Markus Warmuth

As a long-time advocate for industry collaboration and data-driven drug discovery. Markus brings over 20 years of immuno-oncology and precision medicine drug development expertise to IMV. He currently serves as a Venture Partner at Versant Ventures and Chief Executive Officer of Monte Rosa Therapeutics. He had joined versant from Third Rock Ventures. where he worked as an ElR and played an integral role in the venture capital firms' formation of new biotech companies. Prior to his role at Third Rock. Markus spent seven years as the Chief Executive Ofñicer of H3 Biomedicine. a biopharmaceutical company that specializes in the discovery and development of genomics-based precision oncology treatments. Markus has also previously served in multiple roles at the Novartis Institute for Biomedical Research (NIBR) and the Genomics Institute of the Novartis Research Foundation (GNF). including as the Director of Kinase Biology. Head of Oncology Pharmacology. He earned his MD from Ludwig Maximilian University family in Boston, MA. Munich, Germany.